Search Results
Your search for ,aGO matches 1420 pages
Showing 1401 - 1420Disparities Persist in Early-Stage Breast Cancer Treatment
Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....
Study Identifies Novel Genomic Changes in Lung Adenocarcinoma
Researchers from Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other centers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these mutations could potentially identify a...
Excess Risk of Chronic Late Effects of Treatment in Children With Standard-Risk ALL
Given the changes in treatment of children with acute lymphoblastic leukemia (ALL), the risk of late effects in those treated with current protocols may be different from that in children treated decades ago. In a study of survivors of childhood standard-risk ALL reported in The Lancet Oncology,...
St. Jude Children’s Research Hospital Appoints James R. Downing, MD, as CEO
St. Jude Children’s Research Hospital announced the appointment of James R. Downing, MD, as its new CEO, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. He succeeds William E. Evans,...
ASCO 2014: Lenvatinib Yields High Response Rates, Delays Progression in Patients With Radioiodine-Resistant Differentiated Thyroid Cancer
A phase III, multicenter, double-blind, placebo-controlled study found that the oral targeted drug lenvatinib is highly effective among patients with differentiated thyroid cancer resistant to standard radioiodine therapy. “The main result is an extraordinary improvement in progression-free...
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...
The Cancer Community Mourns the Passing of Selma Schimmel
The cancer community is mourning the death of Selma Schimmel who passed away on May 21, 2014, from malignant psoas syndrome, a complication of ovarian cancer. Ms. Schimmel died at Providence Tarzana Medical Center near her home in Los Angeles, California. She was 59. A tireless and fierce advocate ...
Experimental Drug Shows Promise for Treatment-Resistant Leukemia
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. The study by Ma et al, published in Blood, found that ...
NCCN Advocates for Universal Lynch Syndrome Screening in Newly Diagnosed Colorectal Cancer
The National Comprehensive Cancer Network (NCCN) is recommending that newly diagnosed colorectal cancer patients be screened for Lynch syndrome, previously called hereditary nonpolyposis colorectal cancer. The NCCN’s proactive position should greatly help identify individuals and their...
Prostate Health Index May Provide New Tool to Identify Patients Assigned to Watchful Waiting Who Require Immediate Treatment
A simple tool called “phi” appears to be able to identify which patients assigned to active surveillance for prostate cancer are more likely to require treatment. Phi, or the prostate health index, is calculated from three serum measurements: PSA, free/total PSA, and a new measurement,...
Afatinib Improves Progression-Free Survival vs Cisplatin/Gemcitabine in First-Line Treatment of Asian Patients With Advanced EGFR-Mutant NSCLC
Afatinib (Gilotrif) improves progression-free survival compared with pemetrexed (Alimta)/cisplatin in first-line treatment of patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). In the phase III LUX-Lung 6 trial reported in The Lancet Oncology, Wu ...
ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma
There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...
Best of ASCO 2013: Off-Label Prescribing of Chemotherapy Drugs Is Common but Most Meets NCCN Compendium Criteria
Off-label prescribing of drugs remains common in oncology, but about two-thirds of off-label prescribing is consistent with the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, according to a study reviewed at Best of ASCO Chicago by Monika K. Krzyzanowska, MD, MPH, of ...
Sanford-Burnham Researchers Map a New Metabolic Pathway Involved in Cell Growth
Deciphering the body's complex molecular pathways that lead to disease when they malfunction is highly challenging. Researchers at Sanford-Burnham Medical Research Institute now have a more complete picture of one particular pathway that can lead to cancer and diabetes. In a study published in...
New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies
Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...
Two HIV Patients Show No Signs of Disease Following Bone Marrow Transplants for Hodgkin Lymphoma
Timothy Henrich, MD, Associate Physician in the Division of Infectious Disease at Brigham and Women’s Hospital in Boston, reported that two patients with long-standing HIV infections have no detectable levels of the disease in their blood cells, even though they stopped taking their...
ASCO 2013: Top Five Things Oncologists Need to Know about Cancer in Older Adults
A workforce shortage of geriatricians and other health professionals trained and certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, ...
New Diagnostic Technology May Lead to Individualized Treatments for Prostate Cancer
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, has enhanced a device they developed to identify and “grab” circulating tumor cells (CTCs) that break away from cancers and enter the blood, often leading to the...
Genetic Risk Strategies Needed for Young, Black, Female Breast Cancer Patients, Moffitt Cancer Center Study Shows
Researchers at Moffitt Cancer Center and colleagues in Canada have published study results focused on black women younger than 50, a population disproportionately afflicted with and dying from early-onset breast cancer compared to their white counterparts. The research published in The...
Researchers Discover Promising Prognostic Marker for Aggressive Breast Cancer
A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of...
